The purpose of these one-year, $10,000 awards is to promote research opportunities to resident/fellows early in their careers by funding clinical or laboratory-based research projects focused on better understanding the prevention, early detection, behaviors that impact melanoma risk, biology and treatment of melanoma, including cutaneous, ocular, mucosal, pediatric, etc. In addition to awards focused on any aspect of melanoma research, we are pleased to also offer at least one award focused specifically on ocular melanoma research. Applications will be accepted until February 3, 2025 at 5:00 PM ET. Additional information can be found in the 2025 Resident/Fellow Grant RFP and Proposal Central.

The purpose of this one-year, $50,000 pilot proposal award is to focus on novel, innovative clinical/translational melanoma research. The grant principal investigator (PI) must be from an MRFBC institution, CO-PIs/key personnel may be from non-MRFBC sites. A list of participating MRFBC institutions can be found here. Applications must be focused on translational or clinical work that utilizes human specimens, macromolecules derived from the human tissue, or patient reported outcome measures. Successful applications will emphasize novel, innovative proposals designed to accelerate research and treatment development for melanoma patients. Applications will be accepted until March 31, 2025 at 5:00pm ET. Additional information including eligibility requirements can be found in the 2025 MRFBC Pilot Translational Award RFP and Proposal Central.

The purpose of these two-year, $125,000 awards is to promote research opportunities to established melanoma researchers, or senior researchers working in closely related fields who wish to move into melanoma research. This year, in addition to general EIAs, the MRF will offer 1) a grant focused on either defining lethal melanoma and/or identifying lethal melanoma biomarkers at the patient, tumor and/or blood level (e.g. patient risk stratifications, gene expression profiles, ctDNA monitoring etc.) in honor of Katie Morgan (Lethal Melanoma EIA or LM EIA) and 2) a grant focused on pediatric melanoma (PED EIA). For the LM EIA, the grant must be focused on either defining lethal melanoma and/or identifying lethal melanoma biomarkers at the patient, tumor and/or blood level. For the PED EIA, the grant must focus on any aspect of pediatric melanoma.  Applications will be accepted until March 31, 2025 at 5:00 PM ET. Additional information can be found in the 2025 Established Investigator Award RFP and Proposal Central.

The purpose of these two-year, $50,000 awards is to promote research opportunities to junior melanoma researchers to generate the groundwork that can leverage additional grant funding from other funding bodies. As such, recipients must be either postdoctoral fellows with less than five years of postdoctoral experience or a research associate, instructor, assistant professor or the equivalent. Applications will be accepted until March 31, 2025 at 5:00 PM ET. Additional information can be found in the 2025 Career Development Award RFP and Proposal Central.

The purpose of these one-year, $3,000 awards is to promote research opportunities to medical students early in their careers by funding clinical or laboratory-based research projects focused on better understanding the prevention, early detection, behaviors that impact melanoma risk, biology and treatment of melanoma, including cutaneous, ocular, mucosal, pediatric, etc. This grant award is $3,000 for one year. Additional information can be found in the 2025 Medical Student Grant RFP and Proposal Central.

The purpose of this two-year, $250,000 award ($125,000 each year) is to promote translational melanoma research opportunities to principal investigators (PI) who are from an MRFBC institution. A list of participating MRFBC institutions can be found here. The grant PI must be from an MRFBC institution, additional institutions may include non-MRFBC sites. Applications must be focused on translational melanoma research of cutaneous or rare subtypes such as ocular, mucosal, pediatric and acral lentiginous melanomas. Successful applications will emphasize novel, innovative proposals designed to accelerate research and treatment development for melanoma patients. Additional information including eligibility requirements can be found in the 2025 MRF Breakthrough Consortium Team Award RFP and Proposal Central.